# IOV-COM-202 (NCT03645928)

> Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03645928
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Iovance Biotherapeutics, Inc.
- Conditions: Metastatic Melanoma; Squamous Cell Carcinoma of the Head and Neck; Non-small Cell Lung Cancer
- Interventions: Lifileucel; LN-145; Pembrolizumab; LN-145-S1; Ipilimumab; Nivolumab; Nivolumab-relatlimab; Cisplatin; Carboplatin; Paclitaxel; Nab paclitaxel; Pemetrexed
- Enrollment: 225
- Primary outcome: Objective Response Rate
- Primary outcome: Safety Profile Measured by Grade ≥3 TEAEs
- Primary outcome: Percentage of patients for whom lifileucel is successfully manufactured and meets release specification

## Indexed commentary on IOV-COM-202 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=iov-com-202-nct03645928